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ype 2 diabetes is caused by a complex set of
interactions between genetic and environmental
factors. Recent work has shown that human type
2 diabetes is a constellation of disorders associ-
ated with polymorphisms in a wide array of genes, with
each individual gene accounting for 1% of disease risk
(1). Moreover, type 2 diabetes involves dysfunction of
multiple organ systems, including impaired insulin action
in muscle and adipose, defective control of hepatic glu-
cose production, and insulin deﬁciency caused by loss of
-cell mass and function (2). This complexity presents
challenges for a full understanding of the molecular path-
ways that contribute to the development of this major
disease. Progress in this area may be aided by the recent
advent of technologies for comprehensive metabolic anal-
ysis, sometimes termed “metabolomics.” Herein, we sum-
marize key metabolomics methodologies, including
nuclear magnetic resonance (NMR) and mass spectrome-
try (MS)-based metabolic proﬁling technologies, and
discuss “nontargeted” versus “targeted” approaches.
Examples of the application of these tools to diabetes and
metabolic disease research at the cellular, animal model,
and human disease levels are summarized, with a partic-
ular focus on insights gained from the more quantitative
targeted methodologies. We also provide early examples
of integrated analysis of genomic, transcriptomic, and
metabolomic datasets for gaining knowledge about meta-
bolic regulatory networks and diabetes mechanisms and
conclude by discussing prospects for future insights.
In principal, metabolomics can provide certain advan-
tages relative to other “omics” technologies (genomics,
transcriptomics, proteomics) in diabetes research: 1) Es-
timates vary, but one current source, the Human Metabo-
lome Database (HMDB)-Canada (3), currently lists 6,500
discrete small molecule metabolites, signiﬁcantly less than
the estimate of 25,000 genes, 100,000 transcripts, and
1,000,000 proteins. 2) Metabolomics measures chemical
phenotypes that are the net result of genomic, transcrip-
tomic, and proteomic variability, therefore providing the
most integrated proﬁle of biological status. 3) Metabolo-
mics is in theory a precise tool for discerning mechanisms
of action and possible toxicological effects of drug thera-
pies. However, metabolomics is still a ﬁeld in its infancy,
with signiﬁcant limitations and potential for misuse of
technologies and overinterpretation of data. Here we seek
to provide a critical evaluation of progress to date in
application of metabolomics technologies for the under-
standing of diabetes and obesity mechanisms, for sub-
classiﬁcation of different forms of diabetes to assist in
tailoring of therapeutic strategies, and for more detailed
evaluation of the safety and efﬁcacy of drugs used to
treat the disease.
Overview of current metabolomics technologies.
Genome-wide association studies and mRNA proﬁling by
microarray analysis are relatively mature technologies that
have developed to a point where core laboratories that
provide these services are common in both the academic
and private sectors. This is not yet the case for metabolo-
mics. One reason for this is the complexity inherent in
measuring large numbers of intermediary metabolites with
diverse chemical properties in a quantitatively rigorous
and reproducible fashion. Underlying issues include the
wide-ranging concentrations of metabolites in tissues and
bodily ﬂuids (ranging from subnanomolar to millimolar),
problems encountered in efﬁcient extraction of metabo-
lites from different biological matrices (e.g., tissues, blood,
urine), and the chemical diversity of the analytes. Given
these variables, it is perhaps not surprising that no single
technology exists for measurement of all of the metabo-
lites in the “metabolome.” Instead, groups that practice
comprehensive metabolic proﬁling do so with quite di-
verse sets of instruments and methods for data analysis,
the choice of which is inﬂuenced by factors such as cost,
personal experience, and speciﬁc research goals. This
places a large burden on the current core labs and their
clients to ensure reproducibility of their ﬁndings in the
absence of very little standardization of methods across
groups. The U.S. National Institutes of Health has recog-
nized the problem and recently convened a workshop on
development of standardized methods for metabolomics,
leading to a summary of recommendations (4).
The two major instrument platforms for measuring
metabolite levels in biological samples are NMR and MS
(5–13). Raman and infrared spectroscopy (14) and liquid
chromatography coupled to ultraviolet or coulometric
electrode array detection (15) have also been used by
several labs. In general, research groups in the ﬁeld tend to
fall into two camps that adopt either “nontargeted/top-
down” approaches or “targeted/bottom-up” methods as
their core technologies, although a few groups, including
our own, have both kinds of platforms in their repertoire.
Targeted methods. For scientists with core interests in
biological mechanisms rather than biomarkers, knowledge
about the identity of metabolites being surveyed and their
exact concentrations is essential. This encourages some
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quantitative MS-based analyses. These methods focus on
quantiﬁcation of discrete clusters of chemically related
metabolites within a “module” using various combinations
of chromatographic separations technologies and MS in-
struments that are most compatible with the analyte class.
Most targeted metabolic proﬁling methods use stable-
isotope dilution for accurate quantiﬁcation of analytes,
involving addition of several stable isotope–labeled stan-
dards to the biological sample prior to the extraction and
derivatization steps that may be necessary for the partic-
ular MS approach (Fig. 1A). Ideally, each unknown analyte
will be paired with its labeled cognate (often an M3
heavy isotope, e.g., methionine with methyl-D3 methio-
nine, pyruvate with
13C3-pyruvate, etc.) to control for
differences in analyte loss during sample processing and to
compensate for ionization-suppression effects (example in
Fig. 2). One limitation of this approach is the relatively
narrow range of stable isotope–labeled standards that are
available from commercial suppliers and their signiﬁcant
cost. Several groups are now engaged in expanding stan-
dard libraries through custom synthesis, but with the
reagents available today, most labs are limited to measure-
ment of 300 discrete metabolites by targeted methods.
Although targeted metabolomics platforms tend to use
conventional instruments such as electrospray ionization
(ESI)-tandem MS-MS and gas chromatography (GC)-MS,
signiﬁcant challenges must still be overcome in building
rigorous and fully vetted analysis modules for groups of
metabolites. For example, when using GC-MS for measure-
ment of fatty acids or organic acids, chromatography is
performed in the gas phase at a high temperature, and
analytes must be volatile and have sufﬁcient thermal
stability to survive the analysis. To help stabilize the
analytes under study, reactive carboxyl, carbonyl, sulfhy-
dryl, amine, or hydroxyl groups are derivatized by akyla-
tion, oximation, acylation, or silylation (5,11,16,17). These
methods, while effective, add complexity beyond that
already introduced by sample extraction to the analytical
procedures and can result in batch-to-batch variation if not
properly controlled. Similarly, analysis of acylcarnitines or
amino acids/urea cycle intermediates by ESI-MS-MS re-
quires module-speciﬁc derivatization, speciﬁcally treat-
ment with acidic methanol for acylcarnitines and
n-butanol for amino acids/urea cycle intermediates (17–
20). Nevertheless, experience has proven that these meth-
ods can be deployed for reliable and quantitative analysis
of metabolite modules, with coefﬁcients of variation in
replicate assays of major analytes of 15% or less.
Targeted and nontargeted MS-based metabolic analysis
has been applied for years in the clinical diagnosis of
metabolic disease and newborn screening, and today it is
used to detect 40 different genetic diseases of lipid and
amino acid metabolism (21,22). In these applications, less
emphasis is placed on absolute quantiﬁcation of multiple
analytes in a module, since the screen only requires
detection of differences in a single or discrete cluster of
analytes with respect to established laboratory norms. For
example, a defect in HMG-CoA lyase results in large and
speciﬁc increases in 3-hydroxy-isovaleryl-carnitine and
3-methylglutaryl-carnitine species detected by MS-MS,
whereas defects in long-chain 3-hydroxyacyl CoA dehydro-
genase (LCHAD) or mitochondrial trifunctional protein
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FIG. 1. Schematic summary of targeted and nontargeted metabolomics methods. A: When using targeted methods, quantiﬁcation of speciﬁc
analytes is facilitated by addition of stable isotope-labeled standards to the sample prior to the sample extraction and derivatization steps. This
allows reporting of targeted analytes in true units of measure (e.g., mol/l). B: In contrast, when performing nontargeted analysis, the goal is
usually to obtain a global comparison of a large number of analytes across several classes. This is achieved by assaying replicate samples from
contrasting conditions (e.g., drug-treated vs. control cells). Samples are processed and analyzed by MS to generate two independent datasets that
are subjected to univariate and multivariate statistical analysis to identify features that are different between the two conditions, although in
the absence of added standards, the concentration of the analytes is not reported in true units of measure. In addition, for many of the peaks,
the chemical identity of the metabolite cannot be immediately discerned due to limitations in current spectral and chemical standard libraries.
PCA, principal components analysis.
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toyl and 3-hydroxy stearoyl-carnitine metabolites (22).
In more recent years, many of the MS-based targeted
metabolic proﬁling techniques developed for diagnosing
inborn errors of metabolism have been adopted, reﬁned,
and supplemented for studies of mechanisms of disease
pathogenesis. The approach taken in our laboratory has
been to assemble multiple targeted MS-based assay mod-
ules that in aggregate report on several critical metabolic
pathways (17–20). Using a combination of GC-MS and
MS-MS, we are currently able to perform quantitative
analysis of 180 metabolites in seven groups, as summa-
rized in Table 1.
Although the total number of analytes measured with
these tools is small relative to estimates of 6,500 total
metabolites in the metabolome, they are nevertheless
highly useful for understanding changes in metabolic
function under different physiological and pathophysiolog-
ical circumstances. Moreover, expansion of the platform
to include a broader range of analytes of interest in disease
pathogenesis is possible in the near term. A particular
recent focus of the metabolomics community has been in
the area of “lipidomics,” and methodologic advances are
beginning to emerge for proﬁling of phospholipids, pros-
taglandins, and their metabolites (eicosanoids) and sphin-
golipids (9–13). “Shotgun lipidomics,” or the broad survey
of neutral lipids such as triacylglyerols and diacylglyerols,
including the proﬁling of the acyl side chains of these
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FIG. 2. Targeted isotope-dilution analysis of organic acids by GC-MS. When performing targeted isotope-dilution analysis, a group of heavy
isotope standards speciﬁc to the assay module are added immediately following sample homogenization and prior to chromatographic resolution
and MS. A: Total ion chromatogram following GC of a rat liver homogenate in which multiple organic acids are resolved. B: Single ion monitoring
for pyruvate and its corresponding internal standard. Each organic acid peak in the chromatogram (A) contains the target analyte and a heavy
stable isotope as an internal standard, which are resolved and quantiﬁed by mass spectrometry (B) as shown for pyruvate, for example.
TABLE 1
Analyte modules in the Stedman Center laboratory and methods
of analysis
1) Free fatty acids of varying chain length and degrees of
saturation (GC-MS)
2) Total fatty acids (free  esteriﬁed) (GC-MS)
3) Acylcarnitines of varying chain length and degrees of
saturation (representing precursors and products of
mitochondrial fatty acid, amino acid, and carbohydrate
oxidation) (MS-MS)
4) Acyl CoAs of varying chain length and degree of saturation
(MS-MS)
5) Organic acids (TCA cycle intermediates and related
metabolites) (GC-MS)
6) Amino acids, including urea cycle intermediates (MS-MS)
7) Ceramides and sphingolipids (MS-MS)
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focused on separation of neutral lipid species by thin-layer
chromatography followed by capillary GC and detection of
lipid species with a ﬂame-ionization detector (23). More
recent studies use a four-step procedure that includes
organic phase extraction (Bligh and Dyer method), intra-
source separation of lipid species based on propensity for
ionization, separation of ionized species by tandem-MS,
and processing of data to assign molecular species and
determine relative abundances (24). It should be empha-
sized, however, that development of new targeted modules
is not a trivial or inexpensive undertaking, since it requires
acquisition or synthesis of stable isotope–labeled internal
standards, development of extraction procedures that are
efﬁcient for multiple analytes in a class, tailoring of
protocols speciﬁc to the various biological matrices, and
demonstration of quantitative reproducibility of the meth-
ods. The advantage gained is that such tools can be
applied to the understanding of metabolic regulatory
mechanisms in isolated cells, animal models of disease,
and human disease states.
Nontargeted metabolite proﬁling. Nontargeted proﬁl-
ing involves use of NMR, MS, or complementary technol-
ogies for measurement of as many metabolites as possible
in a biological specimen simultaneously, regardless of the
chemical class of the metabolites. In contrast to targeted
proﬁling, in which added internal standards allow quanti-
ﬁcation of speciﬁc metabolites in molar units, nontargeted
metabolomics generally adopts a strategy of comparison
of two biological states and reporting of those analytes
that qualitatively differ in the two states based on statisti-
cal analysis (Fig. 1B). When applied to nontargeted proﬁl-
ing, both NMR and MS have advantages and limitations,
and neither technology can currently be used for surveying
all of the metabolites in a sample in a quantitative fashion.
NMR spectroscopy is theoretically an excellent tool for
nontargeted metabolic proﬁling of all small molecule
metabolites, since the method detects spectral features
emanating from any molecules that contain carbon or
hydrogen (5,7). Moreover, analyses can be conducted
directly in bodily ﬂuids, cells, and even in intact tissues
without the need for chemical extraction or derivatization
of the analytes. These advantages are offset by signiﬁcant
technical challenges, including poor sensitivity, effects of
pH and ionic strength, and the difﬁculty of deconvolution
and normalization of spectra of complex metabolite mix-
tures in biological matrices like plasma, urine, or tissue
extracts. Thus, although NMR spectra are information
rich, lack of sensitivity and data complexity limit quanti-
tative proﬁling to 100 metabolites in most biological
samples by current methods. In some applications, NMR
datasets are analyzed by statistical tools such as principal
components analysis to identify spectral features (often
not identiﬁed as speciﬁc metabolites) that characterize
different biological or disease states (7,25).
MS has the immediate advantage of much higher sensi-
tivity compared with NMR, and the most advanced MS
platforms such as Fourier transform ion cyclotron (FT-
ICR)-MS have the ability to detect metabolites in the
femtomole range (11). Moreover, modern MS platforms
such as those that incorporate time of ﬂight (TOF),
orbitrap, and FT-ICR mass analyzers offer very high mass
resolution and mass accuracy. FT-ICR-MS, for example, is
capable of achieving a mass resolution of 100,000 while
providing mass accurate measurements of 1 ppm. By
coupling such MS instrumentation with high-resolution
chromatographic technologies (e.g., ultra high–pressure
liquid chromatography [UHPLC] and sub-2 m particle
stationary phases), it has become possible to resolve
literally thousands of individual small molecules. Seem-
ingly, these platforms could circumvent problems encoun-
tered when using NMR methods for nontargeted metabolic
proﬁling of complex biological matrices.
In practical reality, the variable lability, solubility, recov-
ery, ionization, and detection of the different analyte
species, coupled with the lack of comprehensive spectral
and stable isotope–standard libraries, make these nontar-
geted MS methods semi-informed (with regard to analyte
identities) and semiquantitative at best. Concerns about
the semiquantitative nature of the methods can be over-
come to some extent by focusing on tightly controlled
biological conditions (e.g., cell lines in tissue culture
studied in response to individual drug, nutrient, or gene
manipulations) and performance of multiple replicate ex-
periments. Under these conditions, statistical ﬁltering can
be applied to peak areas for well-resolved spectral fea-
tures, thereby identifying analytes that change in a consis-
tent fashion. However, ultimate proof of a signiﬁcant
change in an analyte still requires targeted analysis against
an internal standard. The next challenge is identiﬁcation of
the chemical entities represented by the individual peaks.
Help comes from high-accuracy mass measurements af-
forded by current high-end MS instruments. These mass
measurements can be used to query databases such as
METLIN, HMDB, KEGG, Madison Metabolomics Consor-
tium Database (MMCD), and ChemSpider for chemical
formulae whose theoretical masses match the experimen-
tally determined mass, thereby usually providing a strong
starting point for identifying the analyte. In most labora-
tories, current capabilities allow provisional or outright
identiﬁcation of 30% of analytes in complex spectra
obtained through nontargeted MS methods.
Overall, it seems clear that further development of
technologies for nontargeted metabolic proﬁling will be
required before these tools can be maximally informative
in the whole animal or human settings. In contrast, several
examples of application of targeted proﬁling for gaining
new insights into diabetes, obesity, and other chronic
metabolic diseases have emerged recently, as will be
discussed.
Use of targeted proﬁling and NMR-based metabolic
ﬂux analysis for studies of insulin secretion. NMR-
and MS-based tools have been used to investigate the
process of glucose-stimulated insulin secretion (GSIS) in
pancreatic islet -cells (26–35). Stimulation of islet -cells
with glucose causes increases in insulin secretion within
seconds to minutes, and this response is mediated by
signals that are generated by -cell glucose metabolism. A
commonly accepted idea is that increases in the rate of
glucose metabolism in -cells leads to increases in ATP-
to-ADP ratio, which causes inhibition of ATP-sensitive K

channels (KATP channels), membrane depolarization, acti-
vation of voltage-gated calcium channels, and Ca
2-medi-
ated activation of insulin granule exocytosis (36,37).
However, this model clearly does not provide a complete
description of signals that regulate GSIS, since pharmaco-
logic or molecular inhibition of KATP channel activity still
allows robust regulation of insulin secretion by glucose
(38,39). This has led to recent investigation of alternate
metabolic pathways and their byproducts in control of
GSIS (rev. in 35).
Application of
13C NMR-based isotopomer analysis and
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discovery of a critical link between pyruvate carboxylase
(PC)-mediated pyruvate exchange with tricarboxylic acid
(TCA) cycle intermediates (“pyruvate cycling”) and GSIS
and demonstration that these pathways are dysregulated
in lipid-cultured and dysfunctional -cells (26–35). More
recent studies have focused on identiﬁcation of the spe-
ciﬁc pyruvate cycling pathways that may be involved in
generation of signals for insulin secretion. One important
pathway appears to involve export of citrate and/or isocit-
rate from the mitochondria via the citrate/isocitrate carrier
(CIC) and subsequent conversion of isocitrate to -keto-
glutarate (-KG) by the cytosolic NAPD-dependent iso-
form of isocitrate dehydrogenase (ICDc) (30,31) (Fig. 3).
In the foregoing studies, measurement of pyruvate cy-
cling ﬂux was accomplished by incubation of -cells in low
(3 mmol/l) or high (12 mmol/l) concentrations of U-
13C
glucose for several hours, followed by extraction of cells
and analysis of glutamate spectra by NMR. Speciﬁc reso-
nances for each of the carbons of glutamate are affected by
the population of mass isotopomers (glutamate with vary-
ing mixtures of
13C and
12C at each of the ﬁve carbons of
the molecule), and this information can be used to calcu-
late ﬂux through the oxidative (PDH) and anaplerotic (PC)
entry points of the TCA cycle (26,27,40). These methods
reveal that the capacity for GSIS in variously glucose-
responsive INS-1–derived cell lines is tightly correlated
with PC-catalyzed pyruvate cycling activity but not PDH-
catalyzed glucose oxidation (26–28).
Metabolic ﬂux analysis by NMR can be integrated with
static metabolite proﬁling by MS to gain a more complete
picture of fuel-sensing pathways in the -cell. For exam-
ple, GC-MS was used to demonstrate a fall in cytosolic
citrate levels in response to siRNA-mediated suppression
of CIC, as would be expected if a major pathway for export
of citrate from the mitochondria to the cytosol is blocked
(31). Other recent experiments show that glucose stimu-
lation of -cells results in increases in several TCA cycle
intermediates in whole-cell extracts (30,41), but a selective
release of only the early TCA cycle intermediates citrate
and -KG into the medium, with no change in medium
levels of the later TCA cycle intermediates malate, fuma-
rate, or succinate (M. Jensen, H.E. Hohmeier, O.I., and
C.B.N., unpublished observations). These results serve to
conﬁrm that glucose causes a signiﬁcant release of citrate
from the mitochondria and is consistent with the conver-
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FIG. 3. Schematic diagram of a pyruvate/isocitrate cycle implicated in control of GSIS. The cycle is initiated by anaplerotic conversion of pyruvate
to oxaloacetate by PC. This leads to accumulation of the TCA cycle intermediates citrate and isocitrate and their export from the mitochondria
to the cytosol by the CIC. Citrate is then converted to isocitrate by cytosolic aconitase, and isocitrate is converted to -ketoglutarate by the
cytosolic NADP-dependent ICDc. -Ketoglutarate can then serve either as a direct signal for insulin secretion, for example, by serving as a
substrate for -ketoglutarate hydroxylases, or be recycled to pyruvate by one of several mitochondrial or cytosolic pathways that remain to be
deﬁned (dashed lines). Another byproduct of the pyruvate/isocitrate cycle with potential as an insulin secretagogue is cytosolic NAPDH, possibly
acting through Kv channels or the glutathione/glutaredoxin system. This pathway was elucidated by integration of ﬂux analysis by
13C NMR,
targeted metabolic proﬁling by GC-MS and MS-MS, and evaluation of the effects of knockdown of key genes in the pathway, including CIC and
ICDc.
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illustrate two important applications of MS-based meta-
bolic proﬁling in cellular research: 1) use in validation of
the expected metabolic impact of a speciﬁc genetic engi-
neering or pharmacologic manipulation of cellular systems
and 2) integration with ﬂux analysis to provide a complete
picture of changes in metabolic pathways under varying
experimental conditions. Overall, these studies show that
metabolic byproducts of pyruvate/isocitrate cycling may
be an important amplifying signal for control of GSIS.
Possible mediators now under investigation include
NADPH (35,42), -KG or its metabolites (43,44), or GTP
generated by the succinyl CoA dehydrogenase reaction
(45), all of which are direct or downstream products of the
ICDc reaction.
Targeted MS-based metabolic proﬁling applied to
mechanisms of insulin resistance. Lipid infusion or the
ingestion of a high-fat diet results in insulin resistance and
eventual development of diabetes. A prevailing model for
development of diet-induced insulin resistance holds that
mitochondrial fatty acid oxidation is inadequate to deal
with the large load of dietary fat, thus leading to accumu-
lation of lipid-derived metabolites such as diacylglycerols
(DAGs) and ceramides that can activate stress kinases to
interfere with insulin action (46,47) (Fig. 4A). The evi-
dence in support of such a mechanism in induction of
hepatic insulin resistance is considerable and may trans-
late to humans. For example, a short period of caloric
restriction in obese humans improves hepatic insulin
sensitivity in concert with a reduction in liver fat (48). A
possible link between fatty liver and metabolic changes in
peripheral tissues has been uncovered by liquid chroma-
tography-MS analysis of lipids in nondiabetic women with
and without increased liver fat; women with increased
liver fat had elevated levels of esterifed long-chain fatty
acids and ceramides in adipose tissue (49).
Also supporting an important role of hepatic steatosis in
development of insulin-resistant states, whole-animal,
muscle, and liver insulin resistance in rats fed a high-fat
diet are all ameliorated in response to hepatic overexpres-
sion of malonyl CoA decarboxylase (MCD), a gene that
reduces hepatic steatosis by partitioning lipids toward
-oxidation (18). Interestingly, the improvement in muscle
insulin resistance was not correlated with changes in
muscle triglyceride or fatty acyl CoA levels. Instead,
metabolic proﬁling of 37 acylcarnitine species by MS-MS
revealed a decrease in the concentration of lipid-derived
metabolite -OH-butyrylcarnitine (HB) in muscle of
mitochondria 
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FIG. 4. Mechanistic models of lipid-induced impairment of muscle insulin action and supporting metabolomics data. Feeding of diets high in fat
results in muscle insulin resistance, and recent studies suggest the operation of two possible mechanisms for this effect (A). A prevailing theory
is that increased delivery of fat to muscle saturates the capacity for mitochondrial -oxidation, leading to accumulation of bioactive lipid-derived
metabolites such as diacylglycerols and ceramides in the extramitochondrial space and activation of stress/serine kinases that interfere with
insulin action. More recent studies have shown that fatty acid oxidation is actually increased in muscle in response to high-fat feeding but with
no coordinate increase in TCA cycle activity. This results in accumulation of incompletely oxidized lipids in the mitochondria and depletion of
TCA cycle intermediates, possibly resulting in mitochondrial stress and interference with insulin actions. The metabolic changes that underpin
this new mechanism were identiﬁed by targeted GC-MS of organic acids and MS-MS analysis of acylcarnitines in muscle extracts from lean and
obese animals, as summarized in B (data reprinted from ref. 51 with permission). Note that these mechanisms are not mutually exclusive and
could work in concert to impair muscle insulin action. CPT1, carnitine palmitoyltransferase 1; ETS, electron transport system; NEFA,
nonesteriﬁed fatty acid; TCAI, TCA cycle intermediates.
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change in intramuscular ketone metabolism.
The association of improved insulin action with a de-
cline in a mitochondrial lipid-derived metabolite (HB)
encouraged further investigation of the mechanism of
lipid-induced muscle insulin resistance with targeted MS-
based metabolic proﬁling tools (2,50,51). These studies
found that chronic exposure of muscle to elevated lipids in
vitro, or in vivo as a consequence of overnutrition, resulted
in an increase rather than a decrease in expression of
genes of fatty acid -oxidation (50,51). Importantly, this
lipid-induced upregulation of the enzymatic machinery for
-oxidation of fatty acids in muscle was not coordinated
with upregulation of downstream metabolic pathways
such as the TCA cycle and electron transport chain. This
resulted in incomplete metabolism of fatty acids in the
-oxidation pathway, as reﬂected by broad-scale accumu-
lation of mitochondrial lipid metabolites (acylcarnitines)
and a simultaneous decrease in the levels of TCA cycle
intermediates, as revealed by quantitative MS-MS and
GC-MS analysis (50,51) (Fig. 4B).
That these abnormalities may contribute to mitochon-
drial stress and development of insulin resistance is sup-
ported by the ﬁnding that exercising of obese mice
normalizes the elevated acylcarnitines in muscle and re-
stores insulin sensitivity and glucose tolerance (50). Also
supporting the model, mice with global MCD knockout fed
a high-fat diet have suppressed fatty acid oxidation and
reduced acylcarnitine levels, coupled with improvement of
glucose tolerance and insulin resistance (51). Similar
improvements in insulin sensitivity and glucose uptake
have been reported in human myocytes in response to
siRNA-mediated suppression of MCD (52). Also consistent
with these ﬁndings, transgenic mice with muscle-speciﬁc
overexpression of peroxisome proliferator–activated re-
ceptor (PPAR)-, a nuclear receptor that activates -oxi-
dative genes, developed both local and systemic glucose
intolerance (53). In contrast, one recent study reported
improved rather than impaired insulin sensitivity in re-
sponse to overexpression of CPT1 (carnitine palmitoyl-
transferase 1) in muscle (54). Nevertheless, the weight of
recent evidence is consistent with a model in which
lipid-induced insulin resistance in muscle is explained at
least in part by “overload” of mitochondrial lipid oxida-
tion, accumulation of incompletely oxidized fats, and
depletion of TCA intermediates, leading to a condition of
mitochondrial stress that activates signaling pathways
(still to be deﬁned) that interfere with insulin action.
These ﬁndings do not preclude an important role for
accumulation of DAGs, ceramides, or other lipid-derived
metabolites in muscle of animals with diet-induced obe-
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to cause harmful effects.
Other metabolic proﬁling studies have led to the identi-
ﬁcation of a speciﬁc lipid metabolite that might serve to
enhance insulin action (55). Thus, liquid and GC-based
methods were used for quantitative proﬁling of 400 lipid
species in mice lacking expression of fatty acid binding
proteins (FABPs) in adipose tissue (aP2-mal1
/). FABP-
deﬁcient mice fed a high-fat diet fail to accumulate lipids
in adipose tissue and remain insulin sensitive. Adipose
tissue from these animals was enriched in C16:1n7-palmi-
toleate, both as the free fatty acid and in multiple esteriﬁed
species. Infusion of triglycerides containing exclusively
palmitoleate (C16:1) or palmitate (C16:0) into mice for 6 h
resulted in suppression of the entire insulin-signaling
pathway in the case of triglyceride-palmitate, versus a
clear enhancement in insulin action in the case of triglyc-
eride-palmitoleate. Although interesting, this experiment
would have been more convincing if it had included an
additional control of another monounsaturated fatty acid
such as oleate (C18:1). Also, the role of palmitoleate in
control of insulin action in physiological or pathophysio-
logical states remains to be deﬁned, given that palmi-
toleate levels rise in concert with levels of other fatty acids
in obesity (17) and fasting, even though these are states of
clear insulin resistance.
Another study used LC-MS-MS to proﬁle lipids secreted
from the small intestine in response to ingestion of fat
(56). This approach showed an increase in N-acylphos-
phatidylethanolamines (NAPEs) in the circulation. Sys-
temic infusion of the most abundant NAPE decreased food
intake in rats, an effect that could not be ascribed to taste
aversion. The authors also demonstrated that systemically
administered NAPE enters the brain and accumulates in
the hypothalamus. Chronic administration of NAPEs re-
duces food intake and decreases body weight, suggesting
a possible medicinal application in treatment of obesity.
The studies summarized above are examples of use of
targeted metabolic proﬁling technologies for development
of new and testable models of disease pathogenesis and
novel therapeutic strategies. We chose to highlight these
examples because, in each case, the investigators were not
satisﬁed with simple reporting of a metabolic signature of
nutritional manipulation (information) and moved beyond
this point to explore the signiﬁcance of their ﬁndings in
regulation of metabolic fuel homeostasis. Unfortunately,
taking such extra steps to investigate mechanism has been
the exception rather than the rule in application of
metabolomics to diabetes research to this point, and this
must change if the full potential of the technology is to be
realized.
Nuclear receptors, including the family of PPAR-,- 	,
and -
, have emerged as important mediators of insulin
sensitivity.
1H-NMR–, LC-MS–, and GC-MS–based methods
were used to compare PPAR- null and wild-type mice.
The authors reported decreases in glucose, glutamine, and
alanine levels and an increase in lactate, suggesting an
increase in utilization of glucose and amino acids, as might
be predicted from the known effects of PPAR- to promote
the opposing pathways of -oxidation, ketogenesis, and
gluconeogenesis (57). More recently, targeted GC-MS and
LC-MS-MS analysis has provided deeper insights by show-
ing that PPAR- knockout results in fasting hypoglycemia
accompanied by depletion of TCA cycle intermediates and
free carnitine and short-chain acylcarnitines, as well as
accumulation of long-chain acyl CoAs in skeletal muscle
(58). Several of these metabolic abnormalities could be
partially ameliorated by carnitine supplementation. An-
other study surveyed changes in lipid metabolites in obese
and diabetic mice in response to treatment with rosiglita-
zone. These experiments revealed that rosiglitazone in-
duced circulating hypolipidemia, caused substantial
alterations in multiple lipid species in the heart, and
caused accumulation of polyunsaturated lipid species in
adipose tissue (23). These ﬁndings are of particular inter-
est given the propensity of thiazolidinedione drugs to
cause weight gain and accumulation of adipose tissue and
the recent report of a link between these drugs and
increased risk of cardiovascular disease (59), although the
exact relationship between the changes in lipid metabo-
lism and these drug side effects, if any, remain to be
deﬁned. Finally, a very recent study has investigated the
effects of rosiglitazone in normal and diabetic mice with
targeted quantitative measurement of a remarkable 800
metabolites by tandem MS. The authors report that meth-
ylglutarylcarnitine levels are oppositely affected in healthy
and diabetic mice by rosiglitazone and that an enrichment
in phosphatidylcholine relative to lysophosphatidylcholine
levels occurs in diabetic versus normal animals (60).
However, no mechanistic follow-up studies were at-
tempted, and the functional signiﬁcance of either of these
changes therefore remains to be elucidated.
Integration of metabolomics with other “omics”
technologies for studies of metabolic disease mecha-
nisms. Recent studies in plants (61), animal models of
disease (20), and human families with early-onset cardio-
vascular disease (62) have demonstrated that metabolite
proﬁles are heritable and can be integrated with whole-
genome association and microarray proﬁling datasets to
deﬁne gene/metabolite networks. In one such study, dia-
betes-resistant C57BL/6-ob/ob mice were bred with diabe-
tes-susceptible BTBR-ob/ob mice to create an F2 cohort in
which blood glucose and insulin levels were distributed
across a wide range. Liver samples from F2 mice were
subjected to targeted metabolomics and microarray anal-
yses, and integration of these datasets with whole-genome
single nucleotide polymorphism (SNP) analysis showed
clusters of liver metabolites (e.g., a group of amino acids)
mapped to distinct chromosomal regions, suggesting the
presence of genes at those loci that exert metabolic
control on a whole class of metabolites (20) (Fig. 5). Using
reﬁned statistical techniques (63), correlations between
genetic loci, transcripts, and metabolites were used to
develop a model that predicts that the amino acid glu-
tamine acts through alanine:glyoxylate aminotransferase
(Agxt) and arginase 1 (Arg1) to affect phosphoenolpyru-
vate carboxykinase (Pck1) expression (Fig. 6). Consistent
with this predicted network, glutamine addition to primary
hepatocytes causes strong upregulation of Agxt, Arg1, and
PEPCK (20). Moreover, glutamine and PEPCK mRNA
levels are reduced with obesity in diabetes-resistant B6-
ob/ob mice but increased in liver of diabetes-susceptible
BTBR-ob/ob animals (C. Ferrara, C.B.N., A.D. Attie, unpub-
lished observations).
In another study with some similarities in design, F2 rats
from a cross of diabetic Goto-Kakizaki (GK) and normo-
glycemic Brown Norway (BN) rats were surveyed by
nontargeted NMR-based metabolic proﬁling, and this in-
formation was integrated with information about physio-
logic quantitative trait loci (QTL) in the same cross (64).
As with the MS-based study described above, the authors
were able to map spectral features to speciﬁc chromo-
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signiﬁcant QTLs were identiﬁed, including glucose and
benzoate. Subsequent transcriptomic analysis of the par-
ent strains revealed the absence of transcripts for uridine
diphosphate (UDP)-glucuronosyl-transerase-2b (Ugt2b),
an enzyme that metabolizes benzoate and other xenobiot-
ics in mammals. The absence of Ugt2b expression was
subsequently found to be the result of a chromosomal
deletion in the GK strain, demonstrating the ability of
metabolomics to uncover otherwise undetected chromo-
somal abnormalities.
Targeted metabolomics has also recently been inte-
grated with genotyping for understanding the biochemical
impact of common genetic polymorphisms (65). These
authors performed ESI-MS-MS to measure 363 metabolites
in serum of 284 male participants in the KORA study (a
general population study from Germany). Signiﬁcant asso-
ciations were observed between frequent SNPs and
changes in speciﬁc metabolites. Moreover, polymorphisms
in four speciﬁc genes (FADS1, LIPC, SCAD, MCAD) en-
coding metabolic enzymes were linked to perturbations in
the metabolic pathways in which the enzymes are known
to reside. The authors suggest that the combination of
genotyping and metabolic phenotyping may provide new
roadmaps for application of personalized medicine.
These studies represent very early efforts to integrate
metabolomics with other forms of “omics” sciences but
nevertheless serve to illustrate the potential power of
integrated approaches for identiﬁcation of novel metabolic
regulatory networks that contribute to chronic disease
such as type 2 diabetes. As targeted metabolic proﬁling
methods evolve to encompass a larger set of metabolites,
computational methods for integrating this information
with other broad-scale proﬁling datasets must continue to
evolve.
Targeted MS-based metabolic proﬁling for under-
standing of human metabolic disease pathogenesis
Human diabetes and insulin resistance. Targeted
MS-based metabolic proﬁling has been increasingly ap-
plied to studies of human diseases and conditions
(17,19,62,66–73). For example, proﬁling of obese (median
BMI 37 kg/m
2) versus lean (median BMI 23 kg/m
2) humans
revealed a branched-chain amino acid (BCAA)-related
metabolite signature that differentiates the two groups, is
suggestive of increased catabolism of BCAA, and corre-
lates with insulin resistance (17) (Fig. 7). The signature
includes several metabolites that are byproducts of BCAA
catabolism, such as glutamate, -ketoglutarate, C3 acyl-
carnitine (propionylcarnitine), and C5 acylcarnitines (-
methylbutyryl and isovalerylcarnitines). A subsequent
cross-sectional study in sedentary hyperlipidemic subjects
of varying BMI (range 25–35 kg/m
2) identiﬁed several
metabolite clusters (principal components) that explained
most of the data variance and found that the principal
FIG. 5. Metabolite levels are heritable and can be mapped to speciﬁc chromosomes in mice. In this particular study, diabetes-resistant B6-ob/ob
mice were bred with diabetes-susceptible BTBR-ob/ob mice to create a cohort of F2 mice in which individual mice had a wide variation in blood
glucose levels. Whole-genome SNP analysis was integrated with microarray and targeted GC-MS– and MS-MS–based analysis of metabolites of
liver extracts from the F2 animals. This analysis revealed that metabolites can be mapped to speciﬁc chromosomes. Each row represents a SNP
marker, and each column represents a metabolite. The LOD color scale is indicated, showing blue when the B6 allele at that marker results in an
elevated level of the metabolite and red/yellow when the BTBR allele is dominant. Note the clusters of amino acids that map in common to regions
on chromosomes 8 and 9, suggesting the presence of a gene that controls their levels. Figure reproduced with permission from ref. 20. LOD,
logarithm of odds.
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jects tested by the frequently sampled oral glucose toler-
ance test was again one comprised of BCAA and related
metabolites (67). To test the possible relevance of this
ﬁnding for development of obesity-related insulin resis-
tance, rats were fed one of several diets—high fat (HF),
HF with supplemented BCAA (HF/BCAA), or standard
diet. Despite having reduced food intake and weight gain
equivalent to the standard diet group, HF/BCAA rats were
equally as insulin resistant as HF rats. Insulin resistance
induced by HF/BCAA feeding was accompanied by
chronic activation of mTOR and JNK and serine phosphor-
ylation of IRS1(ser307). Moreover, HF/BCAA-induced insulin
resistance was reversed by the mTOR inhibitor rapamycin.
These ﬁndings show that in the context of a poor dietary
pattern of increased consumption of fat, BCAAs make an
independent contribution to development of obesity-asso-
ciated insulin resistance.
Targeted proﬁling has also been applied during an oral
glucose tolerance test in human subjects (68,69). In two
small independent groups of normal non–insulin-resistant
individuals (n  22 and 25), glucose ingestion caused
signiﬁcant changes in 18 metabolites (other than glucose)
among 191 measured, including some that are involved in
pathways not known to be affected by a glucose load (bile
acids and purine degradation products) (68). The metab-
olites that changed signiﬁcantly were also reﬂective of the
known effects of insulin on proteolysis, lipolysis, ketogen-
esis, and glycolysis. A third group of mildly glucose
intolerant and hyperinsulinemic subjects were also stud-
ied and found to have blunted glucose-induced changes in
the metabolic markers of key anabolic pathways relative
to those reported for the normal subjects. Moreover, 6 of
the 18 metabolites identiﬁed as “glucose responsive” in the
studies of normal subjects were found to correlate signif-
icantly with fasting insulin levels, used as a surrogate of
insulin sensitivity. Among these were all three branched-
chain amino acids, lactate, and -hydroxybutyrate. An-
other group applied nontargeted UPLC-qTOF-MS analysis
during oral glucose tolerance testing of 16 normal individ-
uals and found by multivariate statistical analysis that free
fatty acids, acylcarnitines, bile acids, and lysophosphati-
   D2Mit51
    (162.2)
  D4Mit190
     (149.2)
  D5Mit183
     (52.2)
 D7Mit117
   (25.3)
D9Mit182
  (101.5)
   D13Mit76
     (106.8)
D8Mit45
  (86.6) 
D2Mit411
  (159.0)
D7Mit294
   (22.7)
D14Mit126
    (20.2)
D2Mit395
  (122.3)
D9Mit20
 (110.6)
D18Mit177
    (41.2)
D2Mit106
  (132.4)
D13Mit91
   (46.2)
D2Mit263
  (161.8)
D5Mit240
  (108.2)
D8Mit249
   (80.2)
D15Mit252
    (22.6)
D4Mit37
 (116.2)
D10Mit233
   (114.1)
D1Mit64
  (13.0)
D9Mit207
   (60.7)
Slc38a3
Agxt
Slc1a2
Ivd
Ass1
Pck1
Arg1
Glx
Node1
Glx
Slc1a2
Glx
Ivd
Agxt
Ivd
Slc1a2
Arg1
Node 2
Agxt
Glx
Slc1a2
Agxt
Arg1
Slc1a2
Ivd
Pck1
LOD Score
1.67
0.72
0.35
0.55
3.87
2.52
0.10
3.86
p-value
0.05
0.25
0.41
0.30
<0.001
0.04
0.45
<0.001 phosphoenolpyruvate 
carboxykinase (Pck1):
key gluconeogenic 
enzyme
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the glucose bolus (69). These studies demonstrate how
metabolomics can provide a more detailed picture of
metabolic status of normal and pre-diabetic subjects,
which with further development could contribute to more
exact subclassiﬁcation of different forms of diabetes,
leading to more judicious and effective use of drug thera-
pies. However, in order for this to be fully realized, more
effort must be focused on the testing of mechanistic
hypotheses that emanate from initial associations of met-
abolic signatures and disease states.
Human cardiovascular disease. MS-based metabolic
proﬁling has been applied to cardiovascular disease. In
one study, LC-MS analysis was applied to subjects with
exercise-inducible ischemia compared with normal con-
trol subjects (70). Blood samples were taken immediately
before and immediately after exercise, and levels of 173
known and several more minor intermediary metabolites
were measured. A number of metabolites were found to be
discordant between the two groups, including lactate,
byproducts of AMP metabolism, and metabolites of the
citric acid cycle. Using the six most discordantly regulated
metabolites, a metabolic ischemia risk score was derived.
As the number of subjects was quite small in this study,
follow-up studies will be required to conﬁrm or refute
these interesting initial ﬁndings.
MS–MS– and GC-MS–based metabolomics have also
been applied to subjects from multiple generations within
eight multiplex families with familial early-onset cardio-
vascular disease (CVD) (62). Even after adjusting for
variables such as diabetes, hypertension, dyslipidemia,
BMI, age, and sex, multiple individual metabolites and
metabolite clusters identiﬁed by principal components
analysis were found to be highly heritable within families,
including groups of amino acids (arginine, glutamate,
alanine, ornithine, valine, leucine/isoleucine), free fatty
acids (arachidonic, linoleic), and acylcarnitines. Interest-
ingly, families in this study showed two distinct metabolite
proﬁles that tracked with their clinical characteristics,
suggesting different genetic backgrounds and consequent
variation in control of key metabolic pathways that con-
verge on CVD. Current studies are focused on applying the
same metabolic proﬁling tools to nonfamilial populations
of patients at risk for cardiovascular events. Based on our
understanding thus far, targeted metabolomic proﬁles
show promise for predicting CVD and subsequent events
in high-risk families and even in the general population.
Other studies have recently emerged in the realm of
application of metabolomics for the understanding of
metabolic lesions in heart failure and myocardial infarc-
tion. In one study, LC-MS–based proﬁling of 200 metab-
olites was performed on subjects undergoing planned
myocardial infarction via alcohol-mediated septal ablation
or on subjects with spontaneous myocardial infarction or
undergoing elective coronary angiography, as positive and
negative control subjects, respectively (71). Five metabo-
lites were altered in both spontaneous and planned myo-
cardial infarction, and this metabolic signature may
become useful for early detection of myocardial injury
with further validation. Similarly, GC-MS was used for
targeted analysis of serum samples of 52 patients with
systolic heart failure (ejection fraction of 40% and symp-
toms of failure) and 57 control subjects, resulting in
identiﬁcation of pseudouridine and 2-oxoglutarate (-keto-
glutarate) as two potential biomarkers of the failing heart
(72). One limitation of this study was the extensive differ-
ences between groups with regard to use of medications,
including -blockers, ACE inhibitors, and diuretics, all of
which could have inﬂuenced the metabolic proﬁles. Fi-
nally, targeted ESI-MS was used to measure 63 metabolites
in arterial and coronary sinus blood obtained during
cardiac surgery, before and after ischemia/reperfusion
(73). This work demonstrates that the preexisting ventric-
ular state (left ventricular dysfunction [LVD], coronary
artery disease, or neither condition) is associated with
clear differences in myocardial fuel uptake, both at base-
line and following ischemia/reperfusion. In particular, LVD
was associated with global suppression of metabolic fuel
intake (glucose, fatty acid, and amino acids) and limited
myocardial metabolic reserve and ﬂexibility following
ischemia/reperfusion. Moreover, altered metabolic proﬁles
following ischemia/reperfusion were associated with a
postoperative hemodynamic course. The growing number
of metabolomics studies in the area of heart failure may
ultimately facilitate optimal design of perioperative treat-
ment regimens based on the particular form of CVD and
the metabolic status of the heart.
Nontargeted metabolic proﬁling applied to metabolic
disease research. Given its inherently nonquantitative
nature and lack of ability to identify the majority of
analytes in a given proﬁle, is nontargeted metabolic pro-
ﬁling with MS platforms suitable for studies of disease
mechanisms and etiology? Our perspective is that these
tools must be used with caution in whole-animal or human
studies and are currently best suited to in vitro applica-
tions where the biology can be more tightly controlled.
Support for this position comes from a recent and careful
study of application of nontargeted UPLC-MS to human
serum samples, in which it was concluded that signiﬁcant
analytical drift can be introduced when using new chro-
matographic columns or when attempting to analyze more
than 100 samples in a block (74).
An interesting recent example from the cancer research
ﬁeld further illustrates both the limitations and the prom-
ise of nontargeted approaches (75). LC and GC coupled
with MS was used to perform nontargeted proﬁling on
1,100 individual metabolites in prostate tumor explants,
blood, and urine from biopsy-positive cancer patients and
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FIG. 7. A branched-chain amino acid–related metabolite cluster that
correlates with insulin resistance in humans. Targeted metabolic pro-
ﬁling by MS-MS and GC-MS was performed on obese, insulin-resistant,
but nondiabetic humans and a group of lean controls. Principal com-
ponents analysis (PCA) revealed that the cluster of statistically re-
lated metabolites (principal component) with the strongest differences
between obese and lean subjects was one comprised of the branched-
chain amino acids leucine/isoleucine and valine, glutamate/glutamine
(glx), C3 and C5 acylcarnitines, and the aromatic amino acids phenyl-
alanine and tyrosine. A plot of each individual’s principal component
score against their homeostasis model assesment index score (a mea-
sure of insulin sensitivity) is shown, indicating signiﬁcant correlation
(r  0.58; P < 0.0001). Data reprinted with permission from ref. 17.
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sured in physical units (nmol or mol) but rather in
relative units in the cancer patients versus the control
subjects. No meaningful differences were found in metab-
olite proﬁles in urine or blood of cancer subjects com-
pared with control subjects. In contrast, statistically
meaningful increments were found in a small subset of
metabolites in tumor explants, particularly in metastatic
tumors relative to benign prostate. Six metabolites were
found to increase with progression from benign prostate
to localized cancer to metastatic cancer, including sar-
cosine, a glycine metabolite. Importantly, the authors then
developed a targeted stable isotope–dilution method for
quantitative measurement of sarcosine and found it to be
elevated by 10- to 20-fold in metastatic tumors compared
with benign prostrate. They also showed that manipula-
tion of enzymes of sarcosine metabolism inﬂuenced pros-
tate cancer invasion. These results show that nontargeted
MS methods are able to detect changes in metabolites
within the tissue of origin of the metabolic variability.
However, the changes in sarcosine may only have been by
the semiquantitative nontargeted approach because the
changes were very large in magnitude. Nevertheless, this
study is one of the rare but welcome examples of transla-
tion of a metabolic proﬁle associated with disease to
actual mechanistic investigation.
There has been limited application of nontargeted MS-
based metabolomics to diabetes research to date. In one
study comparing pre-diabetic insulin-resistant to healthy
and insulin-sensitive individuals, a complex set of technol-
ogies including LC-MS and Fourier-transform ion cyclo-
tron resonance (FTICR)-MS coupled with multivariate
statistical analysis was used to identify a single metabolite,
3-hydoxyhippuric acid, as a biomarker of the insulin-
resistant state (76). In another study, GC-MS coupled with
multivariate statistical analysis was used to evaluate the
metabolic impact of three diabetes drugs, rosiglitazone,
metformin, and repaglinide, in newly diagnosed type 2
diabetic subjects (77). Abnormalities in several amino
acids and fatty acids were reported in diabetic compared
with healthy subjects, and rosiglitazone was shown to
correct more of these abnormalities than the other two
drugs. The signiﬁcance of these proﬁles in terms of
molecular mechanisms or disease progression remains to
be addressed.
Similar issues and other problems have emerged when
using nontargeted
1H NMR for human studies. A recent
study reported that NMR-based metabolic proﬁles can
predict the presence and severity of coronary artery
disease (78). Partial least-squares discriminant analysis
was used to identify peaks in the major lipid regions of the
spectra that appeared to provide separation between the
groups. The speciﬁc lipid species involved were not iden-
tiﬁed by this analysis, although it was suggested that
choline-containing metabolites were particularly diagnos-
tic. However, a subsequent study using very similar tech-
niques demonstrated that the predictive value of the
NMR-based metabolic proﬁles was weak when other fac-
tors such as sex and use of medical interventions such as
statins were taken into account (79). This second group of
authors demonstrated that the
1H NMR technique could
identify male versus female subjects with 100% accuracy
but was much less able to identify statin users or subjects
with CVD, despite expectations of substantial changes in
lipid proﬁle in the former group. Based on these ﬁndings,
it seems clear that
1H NMR is currently not a substitute for
the more invasive procedure of angiography in the diag-
nosis and staging of CVD.
An intriguing and more promising recent application of
1H NMR–based metabolic analysis has been to study the
inﬂuence of intestinal bacteria (microbiota) on develop-
ment of obesity and metabolic diseases (80). Indeed,
inoculation of germ-free mice with microbiota from the
cecum of normal mice causes an increase in body fat
content and appearance of insulin resistance within 14
days of transfer (81).
1H NMR–based metabolic proﬁling of
plasma and urine samples from a mouse strain known to
be susceptible to hepatic steatosis and insulin resistance
(129S6) versus a strain with relative resistance (BALBc)
revealed low circulating levels of plasma phosphatidylcho-
line and high levels of methylamines in urine in the 129S6
strain (80). The authors propose that the increased pro-
pensity of the 129S6 strain for metabolic disease could be
due to increased metabolism of phosphatidylcholine to
methylamines by intestinal bacteria, resulting in a reduced
pool for the assembly of VLDL particles, leading to depo-
sition of triglycerides in liver. This hypothesis remains to
be tested.
1H NMR has also been applied to research on type 1
diabetes (82,83). One study involved 613 patients with type
1 diabetes and used a novel set of statistical methods to
identify a set of metabolites that stratiﬁed subgroups in the
population according to micro- and macrovascular com-
plications and mortality (83). Another study used LC-MS
for lipid proﬁling, and two-dimensional GC-MS for pro-
ﬁling of organic acids, amino acids, and other small
molecule metabolites to implicate gut microbiota in
development of type 1 diabetes (84). These ﬁndings were
made in a prospective study of Finnish children who
progressed to type 1 diabetes versus control subjects who
remained nondiabetic and autoantibody negative. Children
progressing to diabetes had reduced serum levels of
phosphatidylcholine and succinic acid at birth, possibly
suggestive of increased metabolism of choline by intesti-
nal microbes in the mother or the child. Type 1 diabetic
children also had very high levels of glutamate and
branched-chain amino acids in blood appearing prior to
emergence of autoantibodies, for example, against GAD
and insulin. The source of these very interesting surges in
amino acid levels and their potential mechanistic signiﬁ-
cance remain to be established.
Conclusions and future directions. In the postgenomic
era, biologists and translational investigators alike have
gained a new appreciation for metabolic analysis as a
critical tool for assessing the physiological and pathophys-
iological impact of genetic variation. The current surge in
methods development in the ﬁeld of metabolomics is built
on the foundation of decades of analytical biochemistry
and its use in detecting inborn errors of metabolism. The
major difference between then and now is that the current
emphasis is on methods that allow simultaneous measure-
ment of multiple analytes in a biological sample, whereas
earlier work was often focused on one or a small number
of metabolites per assay. Despite signiﬁcant advances, no
single proﬁling method currently allows simultaneous
analysis of all of the metabolites in the metabolome.
Ultimate achievement of this goal will require continued
intensive development of deeper libraries of chemical
standards, instrument platforms with broad sensitivity
range and high mass accuracy, and likely integration of MS
and NMR methods to gain full analyte coverage. These
advances must be coupled with continued development of
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lomic datasets and their integration with equally complex
genomic, transcriptomic, and proteomic proﬁles. Mean-
while, considerable progress can be made with the cur-
rently available “targeted” technologies that allow proﬁling
of key intermediates of lipid, carbohydrate, purine, pyrim-
idine, and protein metabolism. The examples provided
herein about scientiﬁc insights gained by application of
current tools suggest a broad horizon and provide strong
encouragement for further technology development in this
area. However, it may be apparent to the reader that, to
date, only a subset of the studies cited in this article have
gone beyond the description of metabolic “signatures” that
characterize different physiological, pathophysiological, or
drug-treated states (information) to actual use of the
signatures to pose and then test new hypotheses (knowl-
edge). The paramount challenge of the next phase of
metabolomics investigation is to better harvest the infor-
mation from large datasets to create knowledge about
metabolic regulatory mechanisms, perhaps leading to bet-
ter understanding of perturbations in chronic diseases and
conditions such as type 2 diabetes, obesity, CVD, and
cancer.
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